EMCV Infection: IISc decodes how a virus hijacks host ribosomes

Why in News?

Researchers at the Indian Institute of Science (IISc), Bengaluru, have resolved how the encephalomyocarditis virus (EMCV) recruits a mammalian ribosomal pre-initiation complex to begin making viral proteins. The official IISc release dated 23 July 2026 and The Hindu highlighted the work after its Version of Record appeared in eLife on 25 June 2026.

Using cryo-electron microscopy (cryo-EM), Deepakash Das and Tanweer Hussain reconstructed an EMCV internal ribosome entry site (IRES) bound to the host 40S ribosomal subunit, initiator tRNA and parts of eIF2. The observed structure explains a step in viral translation initiation; it doesn’t show that a drug, vaccine or treatment has already been developed.

• The peer-reviewed paper is titled Structural insights into the recruitment of viral type 2 IRES to ribosomal preinitiation complex for protein synthesis; its Version of Record DOI is 10.7554/eLife.107788.3.
• The team isolated a 48S pre-initiation complex from nuclease-treated rabbit reticulocyte lysate using an EMCV-IRES RNA construct and a protein-based pull-down strategy.
• The maps showed direct contacts between IRES domain I, host ribosomal proteins uS13 and uS19, and the host initiator tRNA.
• The IRES apex appears to mimic part of the host’s 28S ribosomal RNA, helping the viral RNA engage the 40S head at an interface used differently during normal ribosomal-subunit joining.
• IISc proposes testing mimics and candidate compounds against this viral interface next, so therapeutic potential remains a research direction rather than a demonstrated clinical outcome.

The development matters in the context of:

• Viruses lack ribosomes and must depend on host cells to translate viral genetic information into proteins required for replication.
• Cap-independent translation allows several positive-sense RNA viruses to recruit translation machinery through structured RNA elements even when normal cap-dependent host translation is impaired.
• Because EMCV is an animal pathogen with rodent reservoirs and disease in several mammals, the work also connects molecular virology with veterinary health and the One Health approach.

UPSC Relevance

Prelims Relevance

• EMCV is a non-enveloped, positive-sense single-stranded RNA virus in the family Picornaviridae and genus Cardiovirus.
• An IRES is a structured RNA element that recruits ribosomes internally and supports translation initiation without the conventional 5-prime mRNA cap-recognition route.
• A ribosome is the ribonucleoprotein machine that reads messenger RNA and assembles amino acids into a protein.
• The eukaryotic ribosome contains a small 40S subunit and a large 60S subunit; together they form an 80S ribosome.
• The 43S pre-initiation complex contains the 40S subunit, initiation factors and initiator tRNA; recruitment to mRNA produces a 48S complex before 60S joining.
• Initiator tRNA carries methionine to the start codon and helps establish the correct reading frame for protein synthesis.
• Cryo-EM rapidly freezes biological samples in vitreous ice, images them with electrons and computationally combines many particle views into a three-dimensional density map.
• Molecular mimicry occurs when a pathogen’s molecule resembles a host structure or interaction closely enough to exploit a cellular process.
• The World Organisation for Animal Health describes EMCV infection in swine and other mammals; rodent-associated transmission makes animal surveillance relevant.

Mains Relevance

GS Paper 3

• Science and technology: cryo-EM, structural biology and basic research can reveal a pathogen’s molecular dependence on host machinery.
• Biotechnology: structure-guided inhibitor design can begin from a virus-specific RNA-ribosome interface, but must pass biochemical, cellular, animal and clinical validation.
• Health security: viral translation mechanisms can inform broad research platforms for related picornaviruses without implying immediate therapeutic readiness.

GS Paper 2

• Public research institutions: IISc’s work shows the role of publicly supported fundamental science in building long-horizon biomedical capacity.
• Responsible science communication: policy and media must distinguish structural evidence from a tested medicine to avoid overstating early-stage findings.

Essay

• Seeing the invisible: new instruments change public-health possibilities by turning molecular interactions into testable knowledge.
• Basic science and public value: a useful therapy may begin with a patient reconstruction of how a pathogen works.
• Innovation with restraint: scientific promise earns trust when limitations are communicated as clearly as discoveries.

Background and Context

What EMCV is and why it matters

EMCV is primarily an animal virus, and its biological importance extends from molecular research to veterinary disease.

• The World Organisation for Animal Health classifies EMCV as a non-enveloped, positive-sense single-stranded RNA virus of the Picornaviridae family.
• Rodents are important reservoirs, while infections have been reported in swine and other mammals; clinical outcomes can include myocarditis, encephalitis, reproductive disease and sudden cardiac failure.
• A positive-sense RNA genome can function as messenger RNA, but the virus still lacks its own ribosome and must gain access to the host’s translation machinery.
• The IISc study reconstructed a molecular initiation complex in rabbit reticulocyte lysate; it wasn’t an outbreak investigation, an animal-treatment experiment or a human clinical study.
• For UPSC, EMCV is best studied as an example of host-pathogen interaction, viral translation and the links between animal health and biomedical research.

How normal protein synthesis begins

Translation initiation positions a ribosome at the correct start codon before a protein chain can be built.

• In conventional eukaryotic translation, the 43S complex combines the 40S subunit with initiation factors and a ternary complex containing eIF2, GTP and initiator tRNA.
• The cap-binding eIF4F complex, which includes eIF4E, eIF4G and eIF4A, helps recruit this machinery to the capped 5-prime end of cellular mRNA.
• The small subunit generally scans the 5-prime untranslated region until it recognises a suitable AUG start codon, producing a closed 48S complex.
• The large 60S subunit then joins to make an elongation-competent 80S ribosome, which reads codons and adds amino acids to the growing protein.
• This sequence provides the comparison point for understanding how a viral IRES bypasses part of the ordinary cap-dependent recruitment pathway.

IRES as a viral entry route

An internal ribosome entry site is folded viral RNA that acts as a landing and positioning platform for translation machinery.

• IRES elements were first reported in poliovirus and EMCV in 1988, making the concept nearly four decades old even though many structural details remained unresolved.
• EMCV carries a type 2 IRES in its 5-prime untranslated region and uses host factors including eIF4G, eIF4A and the IRES trans-acting factor PTB1.
• Unlike standard cap-dependent initiation, the EMCV IRES can place its start codon directly in the ribosomal P site without the same scanning process.
• Different IRES classes use different strategies: some mimic tRNA-mRNA interactions, while others remodel or bind distinct surfaces of the 40S subunit.
• The IISc result adds a mechanism for a type 2 IRES: its domain I apex contacts the 40S head and initiator tRNA at the inter-subunit face.

How the IISc team captured the complex

The researchers combined biochemical purification with single-particle cryo-EM to stabilise and visualise a normally transient assembly.

• They used an EMCV-IRES-containing RNA and recombinant PTB1 bait to pull a pre-initiation complex from nuclease-treated rabbit reticulocyte lysate.
• A non-hydrolysable GTP analogue helped stall the complex, allowing the team to retain the 40S subunit, initiator tRNA and parts of eIF2 long enough for imaging.
• Cryo-EM samples are rapidly frozen in vitreous ice, which preserves particles without ordinary ice crystals; thousands of two-dimensional views are computationally aligned into three-dimensional maps.
• The analysis produced three major classes: 40S alone, 40S-IRES-initiator tRNA, and a complex that also contained portions of eIF2.
• The relevant reconstructed maps had overall resolutions of about 4.55 angstrom and 5.01 angstrom, sufficient to model major RNA-protein contacts but not every flexible component.

What the structure actually revealed

The central finding is a set of direct contacts that helps explain ribosomal recruitment by EMCV RNA.

• The apex of IRES domain I extends into the inter-subunit region and contacts the 40S head proteins uS13 and uS19.
• A conserved GNRA tetraloop, represented by a GCGA loop in EMCV, contacts the elbow and acceptor-stem region of initiator tRNA.
• The IRES-associated initiator tRNA and parts of eIF2 are shifted toward the 40S head compared with their positions in a canonical closed 48S complex.
• Sequence and structural comparison suggests the IRES apex mimics helix 38 of 28S rRNA, which normally helps the 60S subunit interact with uS19.
• Mutating conserved RNA motifs sharply reduced IRES-driven reporter activity, providing functional support alongside the structural interpretation.
• Related motifs and the 2026 comparison with poliovirus structures support a possible shared strategy among some type 1 and type 2 IRESs, but extension to every IRES class would be unwarranted.

Why one IRES mechanism cannot represent all viruses

IRES is a functional label for internal translation initiation, not a single universal RNA shape or recruitment method.

• The intergenic IRES of cricket paralysis virus can occupy ribosomal sites by mimicking a tRNA-mRNA arrangement and requires fewer conventional initiation factors than EMCV.
• The hepatitis C virus IRES binds another surface of the 40S subunit and can reorganise the initiation machinery through contacts unlike the domain I interaction seen for EMCV.
• EMCV’s type 2 IRES depends on host factors such as eIF4G, eIF4A and PTB1, while its newly resolved apex makes direct contacts with uS13, uS19 and initiator tRNA.
• Poliovirus carries a type 1 IRES. Similar conserved motifs and a separate structural study support comparable ribosome and tRNA contacts, but the surrounding RNA architecture and factor requirements aren’t identical.
• This diversity matters for drug design because blocking one RNA-protein interface may work only for viruses that conserve the relevant geometry, sequence motifs and dependence on that contact.
• For Prelims, avoid the trap that every viral RNA uses an IRES or that every IRES is factor-independent; viral translation strategies differ across families and even across IRES classes.

What cryo-EM did not establish

A structural reconstruction can explain a mechanism without proving that the same interface is already a safe drug target.

• The map captured only part of the flexible EMCV IRES; distinct density for PTB1, eIF4G, eIF4A and eIF3 wasn’t resolved in the reported complex.
• The experiment used a controlled cell-lysate system, not intact infected tissue, a living animal or a patient.
• The study examined translation initiation and reporter activity; it didn’t test whether blocking the interface reduces viral load, disease severity or transmission.
• A candidate inhibitor must be selective enough to disrupt viral recruitment without damaging host protein synthesis or other RNA-dependent cellular functions.
• The trapped complex represents a scanning-arrested initiation state. Molecular assemblies are dynamic, so additional structures are needed to explain how factors rearrange and how the 60S subunit joins.
• The model for parts of flexible IRES domain I used density fitting, computational prediction and comparison with biochemical evidence; local uncertainty is greater than a headline image may suggest.
• The eLife assessment rated the evidence solid and the significance valuable, a useful signal of credible mechanistic work rather than proof of a finished intervention.

Therapeutic promise and wider relevance

The newly described interface offers a hypothesis for drug discovery, not a medicine ready for use.

• The researchers propose designing RNA mimics or compounds that interfere with the IRES-ribosome-tRNA interface and then testing whether viral translation falls.
• Selectivity is plausible because the viral RNA exploits an interaction geometry not used in the same way by ordinary capped host mRNAs, but off-target effects still require experimental testing.
• Conserved motifs in poliovirus and related picornavirus IRESs raise the possibility of a broader platform, although each virus needs structural and functional validation.
• The discovery complements India’s broader science and technology agenda by showing how advanced imaging can convert basic molecular biology into candidate intervention pathways.
• It also resembles the caution needed in other early biomedical results, such as the IISc oral-cancer ultrasound study: promising laboratory evidence is the start of translation, not its endpoint.

Way Forward

Validate the target in infection models

• Test targeted mutations and inhibitors in infected mammalian cells to measure viral protein production, genome replication and infectious-virus yield.
• Confirm whether the interface is conserved and functionally necessary across clinically or veterinary-relevant picornavirus strains.

Build selective inhibitors

• Use structure-guided screening for small molecules, peptides or RNA mimics that disrupt viral contacts at achievable concentrations.
• Measure effects on normal cap-dependent and cellular IRES-mediated translation to establish a credible therapeutic window.

Resolve the remaining complex

• Improve sample stability and resolution to locate flexible factors such as PTB1, eIF4G, eIF4A and eIF3 within the full initiation pathway.
• Use complementary biochemistry and time-resolved structural methods to track the transition from 48S to 80S ribosome formation.

Move through staged preclinical testing

• Assess toxicity, delivery, resistance and pharmacokinetics before advancing any candidate from cells to animal models.
• Treat efficacy against EMCV or poliovirus as unproven until replicated in appropriate infection models and, where justified, regulated clinical trials.

Strengthen Indian structural biology

• Expand shared access to high-resolution cryo-EM, sample-preparation expertise, computing and open structural databases across Indian institutions.
• Link basic virology with veterinary surveillance, medicinal chemistry and public-health priorities while maintaining biosafety and transparent communication.

Conclusion

The IISc study provides a convincing molecular picture of how the EMCV type 2 IRES recruits a host 40S pre-initiation complex. Its strongest contribution is mechanistic: viral RNA contacts the ribosomal head and initiator tRNA, mimics a host rRNA interaction and helps position the machinery at the start codon.

The next test is functional and translational. Researchers must show that disrupting this interface safely suppresses infection in cells and animals before discussing treatment. For UPSC, the larger lesson is that cryo-EM and structural biology can identify new intervention points, while responsible policy keeps discovery, validation and therapy in their correct sequence.

UPSC Practice Questions

Prelims MCQ 1

With reference to the IISc study on EMCV translation, consider the following statements:

1. EMCV is a positive-sense RNA virus belonging to the Picornaviridae family.
2. Its IRES can recruit host translation machinery without depending on the conventional 5-prime cap-recognition route.
3. The study demonstrated an approved broad-spectrum antiviral drug in human trials.

How many of the above statements are correct?

(a) Only one (b) Only two (c) All three (d) None

Answer: (b) Only two

Explanation:

Statements 1 and 2 are correct. EMCV is a picornavirus, and its structured IRES supports cap-independent recruitment of translation machinery. Statement 3 is incorrect because the work resolved a molecular mechanism; it neither produced an approved drug nor conducted a human trial.

Prelims MCQ 2

Which one of the following best describes cryo-electron microscopy in this study?

(a) Sequencing viral RNA by measuring fluorescent nucleotide incorporation (b) Imaging rapidly frozen molecular particles and computationally reconstructing their three-dimensional structure (c) Growing the virus in a live animal and recording disease progression (d) Measuring antibody binding through visible colour change

Answer: (b) Imaging rapidly frozen molecular particles and computationally reconstructing their three-dimensional structure

Explanation:

Cryo-EM preserves molecular complexes in vitreous ice, records many electron-microscope particle views and combines them computationally into a three-dimensional density map. The other options describe sequencing, animal experimentation or an immunoassay, not cryo-EM.

UPSC Mains Questions

1. Explain how an internal ribosome entry site enables cap-independent viral protein synthesis. Using the IISc EMCV study, discuss the observed contacts among viral RNA, the 40S ribosomal subunit and initiator tRNA, and their significance for understanding host-pathogen interactions. (15 marks, 250 words)
2. Cryo-electron microscopy can reveal a drug target but cannot by itself validate a therapy. Evaluate this statement with reference to the EMCV-IRES study, its experimental system, unresolved components, required preclinical evidence and the risks of overstating early biomedical research. (15 marks, 250 words)
3. India’s advanced research infrastructure should connect structural biology, veterinary surveillance and public-health innovation. Discuss how shared cryo-EM facilities, open data, medicinal chemistry, biosafety and One Health coordination can turn fundamental virology into responsible long-term capacity. (15 marks, 250 words)

Sources: Indian Institute of Science and The Hindu.

Frequently Asked Questions